Overview
Teladoc Q3 2025 revenue down 2% yr/yr, beats analyst expectations
Adjusted EBITDA for Q3 2025 beats analyst expectations, despite a 16% yr/yr decline
Company reports Q3 net loss of $49.5 mln, impacted by goodwill impairment charge
Outlook
Teladoc expects 4Q 2025 revenue between $622 mln and $652 mln
Company forecasts full-year 2025 revenue of $2.510 bln to $2.539 bln
Teladoc anticipates full-year 2025 net loss per share of ($1.25) to ($1.10)
Company sees BetterHelp 4Q 2025 revenue growth decline of (8.8%) to (3.8%)
Result Drivers
INTEGRATED CARE GROWTH - Integrated Care segment revenue increased 2% yr/yr, driven by strategic initiatives
BETTERHELP DECLINE - BetterHelp segment revenue decreased 8% yr/yr, attributed to market conditions
GOODWILL IMPAIRMENT - Goodwill impairment charge of $12.6 mln impacted net income, related to Integrated Care segment
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Beat | $626.43 mln | $626 mln (23 Analysts) |
Q3 EPS | -$0.28 | ||
Q3 Net Income | -$49.50 mln | ||
Q3 Adjusted EBITDA | Beat | $69.90 mln | $65.90 mln (22 Analysts) |
Q3 Basic EPS | -$0.28 |
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 21 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Teladoc Health Inc is $9.00, about 7.1% above its October 28 closing price of $8.36
Press Release: ID:nGNXJkxpH
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)